<DOC>
	<DOCNO>NCT01418651</DOCNO>
	<brief_summary>Participants undertake 12-week , open-label study milnacipran well-characterized cohort patient fibromyalgia syndrome ( FMS ) 65 year old investigate short-term efficacy safety drug elderly population . The investigator hypothesize milnacipran effective treat fibromyalgia syndrome ( FMS ) , prove safe patient select absence pre-existing blood pressure abnormalities serious medical condition .</brief_summary>
	<brief_title>Efficacy Safety Milnacipran Treatment Fibromyalgia Elderly Population</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Male female patient . Age 65 year old . Fibromyalgia diagnose accord ACR 1990 criterion . Pain Score ≥ 10 Gracely scale screen baseline assessment . Discontinuation dualacting antidepressant medication , include duloxetine , venlafaxine , tricyclic antidepressant period le 4.5 time drug halflife baseline evaluation . Uncontrolled hypertension ( BP ≥ 140/90 ) screen baseline evaluation . Baseline orthostasis ( document drop SBP ≥ 20 mmHg DBP ≥ 10 mmHg within 3 minute stand ) screen baseline evaluation . Psychosis , active suicidality , current episode major depression severe psychiatric illness , current alcohol/substance abuse dependence assess MINI . Significant cardiovascular disease , include atrial fibrillation dysrhythmia , congestive heart failure , valvular heart disease , QTc prolongation baseline EKG ( &gt; 450 msec ) . Uncontrolled narrow angle glaucoma . History seizure . Use MAO inhibitor drug within last 14 day . Abnormal baseline liver renal function test . Dementia syndrome cognitive impairment could interfere subject 's ability participate fully assessment protocol . Obstructive uropathy male .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>